Pasar al contenido principal

EVOLUCION TUMORAL: DECODIFICANDO LA DESDIFERENCIACION DE LAS CELULAS CANCEROSAS

PID2024-155394OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para la Investigación y el Desarrollo Experimental
Subprograma Subprograma Estatal de Generación de Conocimiento Científico-Técnico y Desarrollo Experimental
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2024
Plan Estatal 2024-2027 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Tfcp2l1 as a central integrator of hypoxia, dedifferentiation, and tumor progression

  • Clemente-González, Cynthia
  • Carnero, Amancio
The gene Tfcp2l1 has emerged as a central player linking key processes in cancer biology: hypoxia, immortalization, dedifferentiation, and tumor progression. Originally identified for its role in maintaining pluripotency in embryonic stem cells, Tfcp2l1 has been found to reappear in various cancers, especially under conditions of low oxygen (hypoxia). Hypoxia, a common feature of solid tumors, triggers the reactivation of developmental genes like Tfcp2l1, enabling cancer cells to dedifferentiate and adopt stem cell-like properties. This dedifferentiation facilitates the immortalization of cells—allowing them to bypass senescence and continue proliferating. Tfcp2l1 contributes to this process by regulating transcriptional networks that suppress differentiation and support self-renewal. Its expression correlates with poor prognosis in several cancers, highlighting its potential role in tumor aggressiveness and resistance to therapy. By acting at the intersection of cellular plasticity, stress adaptation, and oncogenic transformation, Tfcp2l1 may serve as a molecular bridge linking early developmental programs with malignant behaviors. Understanding how Tfcp2l1 integrates signals from hypoxic stress and drives dedifferentiation could uncover new therapeutic targets aimed at reversing or halting tumor progression., This work was supported by grants from the Ministerio de Ciencia, Innovación y Universidades (MCIU) Plan Estatal de I+D+I, Agencia Estatal deInvestigación (AEI) and Fondo Europeo de Desarrollo Regional (MCIU/AEI/FEDER,UE): PID2021-122629OB-I00, PID2024-155394OB-I00 and RED2024-153635-T (iDIFFER network) grants from AEI-MICIU/ 10.13039/501100011033 and, by “ERDF A way of making Europe”, by the “European Union” or by the “European Union Next Generation EU/PRTR” from CIBER de Cáncer(CB16/12/00275), co-funded by FEDER from Regional Development European Funds (European Union); from Consejería de Salud and from Consejería de Economía, Conocimiento, Empresas y Universidad de la Junta de Andalucía (DGP_PIDI_2024_00907). Special thanks to the AECC Foundation (Spanish Association of Cancer Research) for supporting this work (founding ref. GC16173720CARR)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Datos de investigación Set de datos (Dataset)

Additional file 1 of Tfcp2l1 as a central integrator of hypoxia, dedifferentiation, and tumor progression

  • Clemente-González, Cynthia
  • Carnero, Amancio
Ministerio de Ciencia, Innovación y Universidades AEI-MICIU/FEDER CIBERONC Regional Ministry of Economic Transformation, Industry, Knowledge and Universities. Junta de Andalucía, AECC, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The Role of Microbiota in Ovarian Cancer: Implications for Treatment Response and Therapeutic Strategies

  • Blanco, José Ramón
  • Campo, Rosa del
  • Avendaño-Ortiz, José
  • Laguna-Olmos, Mariano
  • Carnero, Amancio
first_pagesettingsOrder Article Reprints Open AccessFeature PaperReview The Role of Microbiota in Ovarian Cancer: Implications for Treatment Response and Therapeutic Strategies by Jose-Ramon Blanco 1,2,3,*ORCID,Rosa del Campo 4,5,*ORCID,José Avendaño-Ortiz 4,6ORCID,Mariano Laguna-Olmos 1ORCID andAmancio Carnero 7,8ORCID 1 Hospital Universitario San Pedro, 26006 Logroño, Spain 2 Centro de Investigación Biomédica de La Rioja (CIBIR), 26006 Logroño, Spain 3 Grupo de Investigación en Cuidados y Salud (GRUPAC), de la Universidad de La Rioja, 26006 Logroño, Spain 4 Centro de Investigación Biomédica en Red Enfermedades Infecciosas (CIBERINFEC), 28029 Madrid, Spain 5 Facultad Ciencias de la Salud, Universidad de La Rioja, La Rioja, 26006 Logroño, Spain 6 Servicio de Microbiología, Hospital Universitario Ramón y Cajal and Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), 28034 Madrid, Spain 7 Instituto de Biomedicina de Sevilla (IBIS)/HUVR/CSIC, Universidad de Sevilla, 41013 Sevilla, Spain 8 CIBER de Cancer (CIBERONC), Instituto de Salud Carlos III, 28029 Madrid, Spain * Authors to whom correspondence should be addressed. Cells 2025, 14(22), 1813; https://doi.org/10.3390/cells14221813 Submission received: 30 September 2025 / Revised: 13 November 2025 / Accepted: 14 November 2025 / Published: 19 November 2025 Downloadkeyboard_arrow_down Browse Figures Versions Notes Abstract Cancer remains a global health challenge (18.1 million new cases in 2020), with incidence projected to reach 28 million within two decades. Ovarian cancer (OC) is the deadliest gynecologic malignancy, usually diagnosed at advanced stages and with poorly understood etiology. Emerging evidence implicates reproductive tract and gut microbiota in OC biology. Microbiota shape carcinogenesis via turnover, immunity, and metabolism; dysbiosis promotes DNA damage, inflammation, and carcinogenic metabolites, engaging multiple hallmarks of cancer. In OC, microbes may reach tumors by local ascent, translocation, or hematogenous spread, originating from vagina, upper reproductive tract, peritoneal fluid, or gut. Lactobacillus-dominant vaginal communities support mucosal integrity, whereas anaerobes disrupt barriers, increase inflammation, and correlate with OC risk; mouse models show vaginal dysbiosis accelerates tumor progression. Distinct microbial profiles in upper reproductive sites and peritoneal fluid associated with immune remodeling. Gut dysbiosis drives barrier loss, immune imbalance, and estrogen reactivation. Microbial metabolites (lipopolysaccharides, short-chain fatty acids) modulate oncogenic pathways, altering epithelial–mesenchymal transition, immune evasion, and drug resistance. Across cohorts, OC tissues and fluids show Pseudomonadota/Bacteroidota enrichment and Akkermansia depletion; fecal microbiota from OC patients accelerates tumor growth in mice, whereas Akkermansia supplementation restores antitumor immunity. Antibiotic exposure and platinum resistance associate with reduced diversity and expansion of lactate-producing taxa. Microbiome-informed interventions–diet, probiotics/postbiotics, fecal microbiota transfer, and selective antibiotics–may augment chemotherapy and immunotherapy. Overall, the microbiome is a modifiable determinant of OC risk, progression, and treatment response, warranting rigorous, standardized, multi-omics studies., This work has been financed by MCIU/AEI/FEDER, UE: PID2024-155394OB-I00; CIBER de Cáncer (CB16/12/00275), and DGP_PIDI_2024_00907, from the Regional Ministry of Economic Transformation, Industry, Knowledge and Universities from Junta de Andalucia; and co-financed by the ISCIII-Dirección General Adjunta de Evaluación y Promoción de la Investigación—Fondo Europeo de Desarrollo Regional “A Way of Making Europe”, Instituto de Salud Carlos III FEDER, together with a grant from the Instituto de Salud Carlos III (MePRAM Project, PMP22/00092), Ministerio de Ciencia e Innovación, financed by NextGeneration European Union funds within the framework of the Resilience and Recovery Fund., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A Darwinian Perspective on Tumor Evolution

  • Carnero, Amancio
Tumor evolution refers to the process by which a tumor develops and changes over time. Tumor evolution is a complex phenomenon that involves a series of stages and factors that contribute to tumor growth, progression and dissemination. These factors may include genetic mutations, changes in gene expression, interactions with the tumor microenvironment, and the immune system response. Tumor evolution can lead to the acquisition of characteristics that allow the tumor to evade the body's control mechanisms and become more aggressive. This may include the capacity for uncontrolled growth, invasion of surrounding tissues, metastasis formation, and resistance to therapy. Understanding tumor evolution is essential to develop more effective prevention, diagnosis and treatment strategies against cancer. Current research is actively studying the mechanisms involved in tumor evolution to identify new targeted therapies and treatment strategies that can address tumor heterogeneity and plasticity. In this review we provide an evolutive perspective of Cancer. From a Darwinian point of view, we present tumors as biological entities subject to similar traits to evolve and develop as natural species. This Darwinian process has strong effects in the clinical tumor as organism behavior, alone or after treatment. From understanding tumorigenesis to treatments, from cancer as disease in its interaction with the microenvironment to therapies; in this review we provide a biological perspective to better understand tumor evolution., This work has been funded by MCIU/AEI/FEDER, UE: PID2024-155394OB-I00; CIBER de Cáncer (CB16/12/00275), and DGP_PIDI_2024_00907, from the Regional Ministry of Eco-nomic Transformation, Industry, Knowledge and Universities from Junta de Andalucia; and co-financed by the ISCIII-Dirección General Adjunta de Evaluación y Promoción de la Investigación—Fondo Europeo de Desarrollo Regional “A Way of Making Europe”., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Artificial Intelligence in Tumor Evolution: Understanding Cancer Complexity Through Multi-Modal Data Integration in Precision Oncology

  • Espinosa-Sánchez, Asunción
  • Carnero, Amancio
This article belongs to the Special Issue The Artificial Intelligence to the Rescue of Cancer Research, Cancer research has undergone a fundamental transformation in recent decades due to the integration of artificial intelligence (AI) models into the study of tumor biology. However, tumor evolution, driven by genetic and phenotypic alterations leading to heterogeneity, resistance and metastasis, remains a major challenge in oncology. To understand these processes is crucial for developing effective therapeutic strategies and improving patient outcomes. Conventional methods often fail to capture the complexity and dynamics of these processes. In contrast, AI tools have the ability to integrate and analyze large-scale multi-omics, imaging and clinical data, offering the capability to decode tumor complexity. AI-driven methods facilitate multi-modal data integration, enabling the recognition of patterns that connect molecular alterations with phenotypic outcomes. In functional genomics, AI tools predict the effects of genetic variants, identify regulatory elements and map dysregulated pathways, thus clarifying mechanisms underlying tumor development and resistance. In the imaging field, deep learning techniques improve tumor segmentation, characterization and longitudinal monitoring, providing more accurate insights into tumor progression and treatment response. Predictive modeling could allow the anticipation of tumor evolution and drug response, supporting adaptive therapeutic plans and real-time treatment adjustments. Moreover, AI supports biomarker discovery, patient stratification and decision support systems that can improve clinical trial design and accelerate the development of personalized therapies. However, these advances raise important ethical challenges, including data privacy, algorithmic bias and the preservation of patient autonomy. Addressing these concerns is essential to ensure the responsible deployment of AI in oncology., This research was supported by grants from Ministerio de Ciencia, Innovación y Universidades (MCIU) Plan Estatal de I + D + I 2018, Agencia Estatal de Investigación (AEI) and Fondo Europeo de Desarrollo Regional (MCIU/AEI/FEDER, UE): PID2024-155394OB-I00 funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”, by the “European Union”; AEI-MICIU/FEDER (iDIFFER network RED2024-153635-T). Additional grants from CIBER de Cáncer (CB16/12/00275), from competitive research projects call within the scope of PAIDI 2020—80% co-financed by the European Regional Development Fund (ERDF) from the Regional Ministry of Economic Transformation, Industry, Knowledge and Universities. Junta de Andalucía (DGP_PIDI_2024_00907). Special thanks to the AECC (Spanish Association of Cancer Research) Founding Ref. GC16173720CARR. This research work was funded by the European Commission—NextGenerationEU, through the Momentum CSIC Program: Develop Your Digital Talent. AES, staff hired under the Generation D initiative, promoted by Red.es, an organization attached to the Ministry for Digital Transformation and the Civil Service, for the attraction and retention of talent through grants and training contracts, financed by the Recovery, Transformation and Resilience Plan through the European Union’s Next Generation funds., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

HOOK2 downregulation compromises the tumorigenic and stemness properties of ovarian cancer cells by increasing endoplasmic reticulum stress

  • Suarez-Martinez, Elisa
  • Espinosa-Sánchez, Asunción
  • Piersma, Sander R.
  • Pham, Thang V.
  • Bijnsdorp, Irene V.
  • Jimenez, Connie R.
  • Carnero, Amancio
[Data availability] All data and materials will be available upon reasonable request. Raw proteomics data can be downloaded from the ProteomXchange repository (dataset identifier PXD050782)., Ovarian cancer stands out as one of the tumors with a high mortality rate in women. Therefore, the search for new therapeutic targets is essential to enhance patient prognosis. There is evidence suggesting that HOOK2, an adaptor protein involved in microtubule transport, may play a role in cancer, particularly ovarian cancer. This study examines the role of HOOK2 in the progression of ovarian tumors. The findings reveal that a decrease in HOOK2 levels leads to diminished growth and cellular migration in ovarian cancer cells, impeding the in vivo formation of tumors. The reduction of HOOK2 is associated with both an increase in endoplasmic reticulum stress and an elevation in cell death, the latter likely caused by the activation of the unfolded protein response. Moreover, the study observes that the decrease in HOOK2 diminishes the properties of cancer stem cells in ovarian cancer, possibly due to the increase in cell death specifically found within these stem cells. Given the profound impact of reduced HOOK2 levels on ovarian cancer cells, this gene emerges as a promising therapeutic strategy for treating ovarian cancer patients., This research was supported by grants from Ministerio de Ciencia, Innovación y Universidades (MCIU) Plan Estatal de I + D + I 2018, Agencia Estatal de Investigación (AEI) and Fondo Europeo de Desarrollo Regional (MCIU/AEI/FEDER, UE): PID2024-155394OB-I00 and PID2021-122629OB-I00 funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”, by the “European Union”; AEI-MICIU/FEDER (RED2024-153635-T (iDIFFER network)). Additional grants from CIBER de Cáncer (CB16/12/00275), from Consejería de Economía, Conocimiento, Empresas y Universidad de la Junta de Andalucía (DGP_PIDI_2024_00907), co-financed by the European Regional Development Fund (ERDF) (Junta de Andalucía). AE-S was hired under the Generation D initiative, promoted by Red.es, an organization attached to the Ministry for Digital Transformation and the Civil Service, for the attraction and retention of talent through grants and training contracts, financed by the Recovery, Transformation and Resilience Plan through the European Union’s Next Generation funds. Special thanks to the AECC (Spanish Association of Cancer Research) Founding Ref. GC16173720CARR for supporting this work., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Role of WDR66 in Stemness, Therapy Resistance and Tumor microenvironment modulation in Head and Neck Cancer

  • Sánchez-Díaz, Laura
  • Espinosa-Sánchez, Asunción
  • Carnero, Amancio
Head and neck cancer comprises a variety of malignant tumors affecting regions such as the oral cavity, pharynx, larynx, paranasal sinuses, nasal cavity and salivary glands. These tumors are highly heterogeneous, making it difficult to identify specific biomarkers and effective treatments, increasing mortality and recurrence rates. Databases analyzed to identify genes with altered expression in tumor tissue showed WDR66 able predict prognosis and survival, in HNSCC, but whose involvement in tumorigenesis is unknown. High WDR66 expression was associated with a worse prognosis, although its overexpression did not significantly alter basic tumor properties in cancer cells in vitro or in vivo. However, we observed an increase in pluripotency factors (OCT3/4, SOX2, KLF4, LIN28), resistance to chemotherapies and a decrease in apoptosis. Consistently, decreasing WDR66 expression using CRISPR showed a reduction in tumorsphere formation, lower expression of pluripotency-related genes, decreased cell migration, and increased sensitivity to cisplatin. These effects were more pronounced in vivo, suggesting a relevant role of WDR66 in the tumor microenvironment. The medium conditioned by cells overexpressing WDR66 promoted migration, maintained the stem cell phenotype, and inhibited immune differentiation, harboring soluble factors involved in progression and metastasis. In this media, we identified several cytokines and growth factors related to inflammation and immune system modulation. In conclusion, WDR66 emerges as a potential biomarker of poor prognosis and a possible predictor of response to immunotherapy, given its impact on cellular pluripotency, treatment resistance and modification of the tumor microenvironment in head and neck cancer., This research was supported by grants from Ministerio de Ciencia, Innovación y Universidades (MCIU) Plan Estatal de I+D+I 2018, Agencia Estatal de Investigación (AEI) and Fondo Europeo de Desarrollo Regional (MCIU/AEI/FEDER, UE): PID2021-122629OB-I00 and PID2024-155394OB-I00 funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”, by the “European Union”; AEI-MICIU/FEDER (iDIFFER network RED2024-153635-T). Additional grants from CIBER de Cáncer (CB16/12/00275), from competitive research projects call within the scope of PAIDI 2020—80% co-financed by the European Regional Development Fund (ERDF) from the Regional Ministry of Economic Transformation, Industry, Knowledge and Universities. Junta de Andalucía (DGP_PIDI_2024_00907). Special thanks to the AECC (Spanish Association of Cancer Research) Founding Ref. GC16173720CARR. AE-S staff hired under the Generation D initiative, promoted by Red.es, an organization attached to the Ministry for Digital Transformation and the Civil Service, for the attraction and retention of talent through grants and training contracts, financed by the Recovery, Transformation and Resilience Plan through the European Union's Next Generation funds., Peer reviewed, Modelo experimental animal
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Environmental Carcinogenesis as a Stochastic Evolutionary Failure of Senescence-Control Systems

  • Blanco, José Ramón
  • Carnero, Amancio
This article belongs to the Special Issue The Role of Cellular Senescence in Health, Disease, and Aging, Environmental carcinogenesis is traditionally explained by the accumulation of genetic alterations induced by exogenous carcinogens. However, most exposed cells do not undergo malignant transformation because intrinsic tumor-suppressive mechanisms limit the expansion of damaged clones. Among these mechanisms, cellular senescence represents a major barrier that restricts proliferation following DNA damage, oncogenic stress, and other carcinogen-induced insults. In this review, we examine environmental carcinogenesis within a probabilistic evolutionary framework in which tumor initiation depends not only on mutation acquisition but also on the ability of rare cells to evade senescence-mediated growth arrest. Environmental carcinogens contribute to cancer development by increasing genomic instability, altering tissue microenvironments, and modifying selective pressures, whereas senescence acts as a critical constraint on clonal evolution. We further discuss how aging, immune surveillance, DNA-repair capacity, and tissue-specific factors influence the likelihood of senescence escape and malignant progression. This integrative perspective highlights carcinogenesis as a multistep stochastic process shaped by the interaction between mutational events, cellular fitness barriers, and microenvironmental selection. Understanding how these factors collectively regulate transformation may improve mechanistic models of cancer risk and identify new opportunities for prevention and early intervention., This research was funded by MCIU/AEI/FEDER, UE: PID2024-155394OB-I00; CIBER de Cáncer (CB16/12/00275); and DGP_PIDI_2024_00907 from the Regional Ministry of Economic Transformation, Industry, Knowledge and Universities of the Junta de Andalucía, co-financed by the Instituto de Salud Carlos III and the European Regional Development Fund (FEDER). Instituto de Salud Carlos III (MePRAM Project, PMP22/00092), Ministerio de Ciencia e Innovación, financed by NextGenerationEU funds within the framework of the Recovery and Resilience Facility., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Functional Interpretation of Differential Gene Expression in Cancer: From Lists to Mechanisms

  • Carnero, Amancio
High-throughput transcriptomic technologies have made differential gene expression analysis a cornerstone of cancer research by generating extensive lists of differentially expressed genes across tumor types and conditions. However, such lists provide limited biological insight without functional and mechanistic interpretation. This review examines the transition from descriptive gene expression profiles to a mechanistic understanding of cancer biology. We discuss integrative approaches that place expression changes within signaling pathways, transcriptional regulatory networks, and protein–protein interaction networks, thereby helping to identify functional modules and candidate upstream regulators. We emphasize the context-dependent nature of gene expression, which is shaped by genetic alterations, epigenetic landscapes, microenvironmental signals, and cellular heterogeneity. We also examine methodological advances, including gene set enrichment analysis, network-based modeling, and integration of genomic, epigenomic, proteomic, metabolomic, and single-cell transcriptomic data. Case studies across cancer types illustrate how mechanistic analyses can reveal context-specific transcriptional programs associated with oncogenic signaling, tumor suppression, metabolic reprogramming, epithelial–mesenchymal transition, and tumor–immune interactions. We highlight potential translational applications, including candidate biomarker discovery, prioritization of druggable targets, rational design of combination therapies, and investigation of therapeutic resistance. Finally, we discuss current challenges and emerging technologies, such as spatial transcriptomics and clustered regularly interspaced short palindromic repeats (CRISPR)-based perturbation screens, that are advancing the field toward dynamic, systems-level models of tumor biology. Integrating computational analyses with experimental validation can help translate transcriptomic data into clinically relevant hypotheses for precision oncology and personalized cancer therapy., This work was supported by MCIU/AEI/FEDER, EU (PID2024-155394OB-I00); CIBER de Cáncer (CB16/12/00275); and the Regional Ministry of Economic Transformation, Industry, Knowledge and Universities of the Junta de Andalucía (DGPPIDI202400907), and was co-financed by the ISCIII–Dirección General Adjunta de Evaluación y Promoción de la Investigación–European Regional Development Fund, “A Way of Making Europe.”, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Tumoral switch in NUMB splicing changes essential transcription pathways and induces malignant properties in tumour cells

  • García-Heredia, J. M.
  • Ortega-Campos, Sara M.
  • Carnero, Amancio
[Data availability] Availability of data and materials All datasets analysed in this study are publicly available. Breast cancer datasets from the Gene Expression Omnibus (GEO, RRID:SCR_005012), including GSE69031, GSE21653, GSE1456, GSE20685, GSE25066, GSE42568, GSE162228, and GSE12093, were used in this study and are publicly available at GEO [78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93]. TCGA-BRCA RNA-seq isoform expression and clinical data were obtained from the NCI Genomic Data Commons (GDC; RNA-seq Level 3 RSEM isoform-normalized data dated 2015–08-06). CCLE expression data were obtained from the Cancer Cell Line Encyclopedia (CCLE; RNA-seq transcript TPM file dated 2018–09-29), and drug-response data were integrated with GDSC (release dated 2023–10-27) after harmonising cell-line identifiers. Breast PDX isoform quantifications and metadata were obtained from the PDMR resource. Key analysis outputs and sample-level annotations, including transcript-level differential expression, pathway enrichment results, metabolic expression matrices, drug-response statistics, and NUMB-score assignments, are provided in the Supplementary Information files (Additional file 3: Tables S2–S10). All custom scripts used for data processing and analysis are publicly available at GitHub (https://github.com/jmgheredia/NUMB-tumoral-switch) and are distributed under an OSI-compliant open-source license (MIT License) [111]. The source code has also been permanently archived in Zenodo with an assigned DOI (https://doi.org/10.5281/zenodo.18522980) [112]., [Background] Emerging evidence indicates that cancer is associated with widespread splicing alterations that generate tumour-specific isoforms. One example is NUMB, an evolutionarily conserved adaptor protein, which produces four isoforms (p72, p71, p66, and p65) through alternative splicing of exons 3 and 9. Although traditionally considered as a tumour suppressor, NUMB has also been reported as an oncogene. We propose that this dual role reflects isoform-specific expression., [Results] Using public databases, we identify a tumour-associated switch in NUMB isoform expression: p72 and p71 are upregulated in tumours, whereas p66 and p65 are more highly expressed in non-tumour tissues. These isoforms show distinct associations with key cellular processes. NUMBL, a NUMB homolog, displays expression patterns similar to p65. We further identify two transcriptional clusters: one characterised by high expression of p72 and p71, and the other by enhanced p66/p65/NUMBL expression. These clusters exhibit differential associations with Notch, WNT/β-catenin, Hedgehog, and Hippo signalling pathways, suggesting isoform-specific regulatory roles. In breast cancer cell lines, we develop a NUMB-score based on isoform expression, which classifies cell lines into biologically distinct groups. The p72/p71-enriched group shows distinct signatures, pathway activity, and drug sensitivity. Application of this score to TCGA-BRCA samples reveals a significant link between high NUMB-score and poor survival, as confirmed by Kaplan–Meier analysis., [Conclusions] We find that NUMB emerges as a potential oncogenic contributor and biomarker in the context of splicing-based precision oncology, highlighting Isoform-specific expression as a clinical determinant of tumour behaviour, pathway activity, and therapeutic response., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This research was supported by grants from Ministerio de Ciencia, Innovación y Universidades (MCIU) Plan Estatal de I + D + I 2018, Agencia Estatal de Investigación (AEI) and Fondo Europeo de Desarrollo Regional (MCIU/AEI/FEDER, UE): PID2024-155394OB-I00 and PID2021-122629OB-I00 funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”, by the “European Union”; AEI-MICIU/FEDER (iDIFFER network: RED2024-153635-T). Additional grants from CIBER de Cáncer (CB16/12/00275), from Consejeria de Salud (PI-0397–2017) and Projects P18-RT-2501; and DGP_PIDI_2024_00907 from the Regional Ministry of Economic Transformation, Industry, Knowledge and Universities. Junta de Andalucía. Special thanks to the AECC (Spanish Association of Cancer Research) Founding Ref. GC16173720CARR for supporting this work., Peer reviewed